➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Colorcon

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for PBT-1033


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PBT-1033?

PBT-1033 is an investigational drug.

There have been 7 clinical trials for PBT-1033. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2019.

The most common disease conditions in clinical trials are Esophageal Neoplasms, Carcinoma, and Endometrial Neoplasms. The leading clinical trial sponsors are xjpfW, NRG Oncology, and National Cancer Institute (NCI).

There are one hundred and eleven US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for PBT-1033
TitleSponsorPhase
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBTJarrow Formulas IncPhase 1/Phase 2
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBTUniversity of California, IrvinePhase 1/Phase 2
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) ApproachUniversity of Maryland, BaltimorePhase 2

See all PBT-1033 clinical trials

Clinical Trial Summary for PBT-1033

Top disease conditions for PBT-1033
Top clinical trial sponsors for PBT-1033

See all PBT-1033 clinical trials

US Patents for PBT-1033

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PBT-1033   Get Started Free Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH)   Get Started Free
PBT-1033   Get Started Free 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY)   Get Started Free
PBT-1033   Get Started Free Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH)   Get Started Free
PBT-1033   Get Started Free Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors Pfizer Inc. (New York, NY)   Get Started Free
PBT-1033   Get Started Free Combination therapies for the treatment of Alzheimer's disease and related disorders The General Hospital Corporation (Boston, MA)   Get Started Free
PBT-1033   Get Started Free Imidazopyridazine compounds Pfizer Inc. (New York, NY)   Get Started Free
PBT-1033   Get Started Free N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides Pfizer Inc. (New York, NY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PBT-1033

Drugname Country Document Number Estimated Expiration Related US Patent
PBT-1033 Argentina AR104982 2035-06-12   Get Started Free
PBT-1033 Australia AU2016276966 2035-06-12   Get Started Free
PBT-1033 Canada CA2989343 2035-06-12   Get Started Free
PBT-1033 China CN109562085 2035-06-12   Get Started Free
PBT-1033 European Patent Office EP3307260 2035-06-12   Get Started Free
PBT-1033 Hong Kong HK1245660 2035-06-12   Get Started Free
PBT-1033 Israel IL256231 2035-06-12   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Medtronic
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.